Why Must APS Antibody Tests Be Repeated 12 Weeks Apart?
At a Glance
Antiphospholipid syndrome (APS) antibody testing is repeated at least 12 weeks later to show that antibodies persist rather than reflect a temporary response to infection, inflammation, or medication. Diagnosis also depends on a qualifying blood clot or specific pregnancy complication.
In this answer
6 sections
If you have been told you need a second antiphospholipid antibody test at least 12 weeks after your first one, it is because doctors need to prove the antibodies are persistent. A diagnosis of antiphospholipid syndrome (APS) generally requires two things: a qualifying clinical event (like a blood clot or specific pregnancy complication) and laboratory findings that are persistent on repeat testing [1] [2]. Because the immune system can temporarily produce these antibodies for reasons unrelated to APS, a single positive test is not enough [3]. Waiting at least 12 weeks to repeat the test confirms that the antibodies remain over time, rather than just being a brief reaction to a passing illness [1] [4]. Waiting for these answers can be stressful, but this interval is essential for your medical team to make safe, long-term decisions about your care.
What Qualifies as a Clinical Event?
Not every blood clot or miscarriage automatically points to APS. The classic clinical criteria require objective confirmation [5] [6]:
- Thrombosis: An objectively confirmed blood clot (such as in a vein or artery).
- Specific Pregnancy Morbidity: This usually means three or more unexplained miscarriages before 10 weeks, an unexplained fetal death at or after 10 weeks, or a premature birth before 34 weeks related to severe preeclampsia or placental insufficiency.
What Causes a Temporary Positive Result?
The immune system is highly reactive. It can produce temporary (transient) antiphospholipid antibodies when stimulated by something else in the environment [3]. Common triggers include:
- Infections: Viral, bacterial, and other microbial infections can trigger a short-lived antibody response. For example, some people with COVID-19 or other acute illnesses develop antiphospholipid antibodies that later resolve [3] [7] [8].
- Inflammation and Autoimmunity: Severe inflammatory conditions, or other autoimmune diseases, can sometimes cause fluctuating antibody levels [9] [10].
- Medications: Certain prescription drugs can trigger a temporary immune reaction that looks like APS on a lab test. These antibodies may fade after the drug is stopped, though not always immediately [9].
Because these temporary antibodies can resolve, the 12-week minimum interval acts as a filter. It helps prevent an incorrect APS label and inappropriate long-term medical management (like being placed on powerful blood thinners indefinitely) based on a passing infection [3].
What Do the Three Antibody Tests Measure?
There are three main tests for APS. It is important to know that Lupus Anticoagulant is a very confusing medical term: it does not mean you have lupus, and it is not a blood-thinning medication. It is simply an antibody that interferes with clotting in a test tube.
| Antibody Test | What It Is | Is It Affected by Blood Thinners? |
|---|---|---|
| Lupus Anticoagulant (LA) | A clot-based test measuring if antibodies are interfering with blood clotting times. | Yes. Blood thinners heavily interfere and can cause false results [11] [12]. |
| Anticardiolipin (aCL) | A solid-phase immunoassay (using IgG or IgM isotypes) measuring antibodies against specific proteins. | Usually not materially affected by blood thinners [13]. |
| Anti-Beta-2-Glycoprotein I (aB2GPI) | A solid-phase immunoassay (using IgG or IgM isotypes) measuring antibodies against specific proteins. | Usually not materially affected by blood thinners [13]. |
What If My Results Change?
It is common for test results to differ between the first and second blood draw. If your second test is negative, it means persistent positivity was not demonstrated on that specific day. It does not automatically prove your first result was temporary or completely rule out APS [3] [14]. Assay variations, different laboratory thresholds, or anticoagulant interference can all affect results.
Antibody levels can also naturally fluctuate over time [14]. In some cases, a patient might lose their positive result for one antibody (like anticardiolipin) while another (like lupus anticoagulant) remains persistently positive [15]. A shift from having one positive antibody to having multiple tests be positive (double-positive or triple-positive) generally indicates a higher-risk profile [11] [16]. However, your treatment is not determined by your antibody count alone.
For those with familial APS, it is helpful to remember that while autoimmune susceptibility can cluster in families, APS is not inherited in a simple parent-to-child pattern. A family history of APS provides important context for your doctor, but your own diagnosis still requires your own clinical event and your own persistent laboratory results.
Classification Criteria vs. Clinical Diagnosis
When researching APS, you might read about strict rules requiring exact antibody levels (titers) and rigid timelines. These are called classification criteria, and they are designed to create reasonably uniform patient groups for research trials [5] [17].
However, research criteria are an imperfect framework for real life, where your doctor makes a clinical diagnosis [17]. Even if your repeat test results fall just short of strict research cutoffs, or if your levels fluctuate, your doctor may still diagnose you with a clinical APS picture based on your unique symptoms and history [17] [18]. Conversely, a borderline positive result does not automatically justify lifelong treatment.
Warning: Do Not Stop Blood Thinners for Testing
If you experienced a blood clot, you were likely placed on blood thinners (anticoagulants). Never hold, switch, or bridge your blood thinners to prepare for a repeat antibody test without explicit, individualized instructions from your medical team.
While the anticardiolipin and anti-beta-2-glycoprotein I tests are usually not materially affected by blood thinners, the lupus anticoagulant (LA) test is highly vulnerable to interference from warfarin, heparin, and direct oral anticoagulants (DOACs) [13] [11]. This drug interference can cause confusing false-positive or false-negative results [12].
Do not assume you will simply be switched to another medication (“bridging”) just for the test. Bridging is not routine solely to obtain a lab result, as it carries its own risks of serious bleeding or triggering a new clot [19] [20]. In some cases, specialized coagulation laboratories can use technical processes to mitigate drug interference, but these methods have limitations [21] [22]. Sometimes, the safest decision your team can make is simply to defer the LA test. Always prioritize your immediate safety over getting a “perfect” lab test.
(Note: If you ever experience sudden shortness of breath, severe chest pain, one-sided weakness, or a swollen and painful limb, seek emergency medical care immediately.)
Common questions in this guide
Why isn't one positive APS antibody test enough for a diagnosis?
What does a negative second APS test mean?
Can blood thinners interfere with APS antibody testing?
Which clinical events are considered when doctors diagnose APS?
Do two or three positive APS antibodies confirm the diagnosis?
Can an infection cause a temporary positive APS result?
Does a family history of APS mean I will inherit it?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.If my second test is negative, does that mean my first result was just temporary, or could my levels be fluctuating?
- 2.Since my family has a history of APS, how does that affect the interpretation of my personal test results?
- 3.Can we safely perform the repeat anticardiolipin and anti-beta-2-glycoprotein I tests while I remain on my current blood thinners?
- 4.If you need to test my lupus anticoagulant, how does the lab handle interference from my specific blood thinner, or should we defer the test?
- 5.Do my symptoms meet the specific clinical criteria for an APS diagnosis, or is another cause more likely?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (22)
- 1
Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies.
Tufano A, Di Minno MND, Guida A, et al.
Seminars in thrombosis and hemostasis 2019; (45(5)):468-477 doi:10.1055/s-0039-1692702.
PMID: 31216589 - 2
[Laboratory diagnosis of antiphospholipid syndrome: From criteria to practice].
Joste V, Dragon-Durey MA, Darnige L
La Revue de medecine interne 2018; (39(1)):34-41 doi:10.1016/j.revmed.2017.02.006.
PMID: 28302338 - 3
Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation.
Martirosyan A, Aminov R, Manukyan G
Frontiers in immunology 2019; (10()):1609 doi:10.3389/fimmu.2019.01609.
PMID: 31354742 - 4
Recent advances in understanding antiphospholipid syndrome.
Bertolaccini ML, Sanna G
F1000Research 2016; (5()):2908 doi:10.12688/f1000research.9717.1.
PMID: 28105326 - 5
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
Barbhaiya M, Zuily S, Naden R, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(10)):1687-1702 doi:10.1002/art.42624.
PMID: 37635643 - 6
Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.
Barbhaiya M, Zuily S, Amigo MC, et al.
Current rheumatology reports 2025; (27(1)):41 doi:10.1007/s11926-025-01202-y.
PMID: 41296194 - 7
COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check?
Favaloro EJ, Henry BM, Lippi G
Seminars in thrombosis and hemostasis 2022; (48(1)):72-92 doi:10.1055/s-0041-1728832.
PMID: 34130340 - 8
Antiphospholipid Antibodies in Critically Ill Patients With COVID-19.
Xiao M, Zhang Y, Zhang S, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2020; (72(12)):1998-2004 doi:10.1002/art.41425.
PMID: 32602200 - 9
Severe Antiphospholipid Syndrome and Diffuse Glomerulonephritis After Adalimumab Treatment in a Patient With Ulcerative Colitis.
Rivera-Burgos I, Vilá LM
Case reports in rheumatology 2024; (2024()):8024757 doi:10.1155/2024/8024757.
PMID: 39529874 - 10
The history of antiphospholipid syndrome.
Tincani A, Fontana G, Mackworth-Young C
Reumatismo 2023; (74(4)) doi:10.4081/reumatismo.2022.1556.
PMID: 36942979 - 11
Testing for the lupus anticoagulant: the good, the bad, and the ugly.
Favaloro EJ, Pasalic L, Selby R
Research and practice in thrombosis and haemostasis 2024; (8(3)):102385 doi:10.1016/j.rpth.2024.102385.
PMID: 38623474 - 12
Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis.
Tripodi A, Cohen H, Devreese KMJ
Journal of thrombosis and haemostasis : JTH 2020; (18(7)):1569-1575 doi:10.1111/jth.14846.
PMID: 32619349 - 13
Antiphospholipid Antibody Testing for Anti-cardiolipin and Anti-β2 Glycoprotein I Antibodies Using Chemiluminescence-Based Panels.
Favaloro EJ, Mohammed S, Vong R, Pasalic L
Methods in molecular biology (Clifton, N.J.) 2023; (2663()):297-314 doi:10.1007/978-1-0716-3175-1_19.
PMID: 37204719 - 14
Loss of antiphospholipid antibody positivity post-thrombosis in SLE.
Khawaja M, Magder L, Goldman D, Petri MA
Lupus science & medicine 2020; (7(1)) doi:10.1136/lupus-2020-000423.
PMID: 33023978 - 15
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers.
Chighizola CB, Willis R, Maioli G, et al.
Autoimmunity reviews 2024; (23(3)):103510 doi:10.1016/j.autrev.2023.103510.
PMID: 38171447 - 16
EULAR recommendations for the management of antiphospholipid syndrome in adults.
Tektonidou MG, Andreoli L, Limper M, et al.
Annals of the rheumatic diseases 2019; (78(10)):1296-1304 doi:10.1136/annrheumdis-2019-215213.
PMID: 31092409 - 17
An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.
Devreese KMJ, Bertolaccini ML, Branch DW, et al.
Journal of thrombosis and haemostasis : JTH 2025; (23(2)):731-744 doi:10.1016/j.jtha.2024.10.022.
PMID: 39510414 - 18
2023 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for antiphospholipid syndrome: good for patients or good for papers?
Devreese KMJ
Research and practice in thrombosis and haemostasis 2025; (9(2)):102735 doi:10.1016/j.rpth.2025.102735.
PMID: 40242190 - 19
Diagnosis and management of the antiphospholipid syndrome.
Chaturvedi S, McCrae KR
Blood reviews 2017; (31(6)):406-417 doi:10.1016/j.blre.2017.07.006.
PMID: 28784423 - 20
Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome.
Paquette M, Miranda S, Xu Y, et al.
Blood advances 2026; (10(9)):3218-3228 doi:10.1182/bloodadvances.2026019610.
PMID: 41843780 - 21
Pretest direct oral anticoagulant removal is highly effective in lupus anticoagulant testing while on direct oral anticoagulants: a real-life experience.
Słaboszewski M, Ząbczyk M, Papuga-Szela E, et al.
Journal of thrombosis and haemostasis : JTH 2026; doi:10.1016/j.jtha.2026.08.023.
PMID: 42665229 - 22
Laboratory assessment of antiphospholipid syndrome: Laboratory data.
Kobylecki CJ, Vedel-Krogh S, Afzal S, Goetze JP
International journal of laboratory hematology 2024; (46(4)):714-721 doi:10.1111/ijlh.14273.
PMID: 38563299
This page is for informational purposes only and does not constitute medical advice. Do not stop, switch, or bridge blood thinners without individualized instructions from your medical team.
Get notified when new evidence is published on familial antiphospholipid syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.